Nuclear Imaging Market Size, Share, Growth, Value and Report 2024-2031

Nuclear Imaging Market Size, Share, Industry, Forecast and outlook (2024-2031)

<h2>Nuclear Imaging Market is segmented By Product Type (Hybrid Pet, Standalone Pet, Hybrid SPECT, Standalone SPECT, Planar Scintigraphy), By Application (Cardiology, Neurology, Oncology, Others), By End-User (Hospitals, Research Centres, Academic Centres, Diagnostic Centres, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2024-2031</h2>

&nbsp;

<h3>Report Overview</h3>

<blockquote>
The Nuclear Imaging Market is expected grow at a CAGR of 12.9% during the forecast period 2024-2031
</blockquote>

Nuclear imaging produces images by detecting radiation from different parts of the body after a radioactive tracer material is administered. Nuclear imaging is a nascent imaging technology that uses a small number of radioactive substances linked to compounds used by the body&#39;s cells or compounds that attach to tumor cells.

&nbsp;

<h3>Nuclear Imaging Market Summary</h3>

<table border="1" cellpadding="1" cellspacing="1">
	<tbody>
		<tr>
			<td>
			Metrics
			</td>
			<td>
			Details
			</td>
		</tr>
		<tr>
			<td>
			Market&nbsp;CAGR
			</td>
			<td>
			12.9%
			</td>
		</tr>
		<tr>
			<td>
			Segments Covered
			</td>
			<td>
			By Product Type,&nbsp;By Application,&nbsp;By End-User,&nbsp;and By Region
			</td>
		</tr>
		<tr>
			<td>
			Report Insights Covered
			</td>
			<td>
			Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.
			</td>
		</tr>
		<tr>
			<td>
			Fastest Growing Region
			</td>
			<td>
			Asia Pacific
			</td>
		</tr>
		<tr>
			<td>
			Largest Market Share&nbsp;
			</td>
			<td>
			North America
			</td>
		</tr>
	</tbody>
</table>

&nbsp;

For More Insights&nbsp;<a href="https://www.datamintelligence.com/download-sample/nuclear-imaging-market" target="_blank">Request Free Sample</a>

&nbsp;

<h3>Nuclear Imaging Market Trends</h3>

Nuclear Imaging Market growth is driven by the increasing focus on personalized medicines and technological advancements in radiotracers. Moreover, growing pharmaceutical industries and the rising prevalence of <a href="https://www.datamintelligence.com/research-report/chronic-disease-management-market" target="_blank">chronic diseases</a> such as cancer will enhance market growth.&nbsp; &nbsp;

The technological advancements in the field of nuclear imaging will drive the market growth&nbsp;

The technological advancements in the field of imaging have always been challenging to practitioners in how best to optimize them in patient care. Over recent years, scientists, researchers, and technologists have been able to bring systems into clinical practice, in which two or even more two standalone diagnostic imaging modalities are combined. Some of those multimodality imaging systems include PET/CT, SPECT/CT, PET/MRI, and PET/SPECT/CT.

Overall usage of nuclear medicine procedures is expanding rapidly, especially as new imaging technologies, continue to improve the accuracy of detection, localization, and characterization of disease, and as automation and miniaturization of cyclotrons and advances in radiochemistry make the production of radiotracers more practical and versatile.

Moreover, the rise in the prevalence of cancer and cardiac ailments is one of the primary drivers for the market. Nuclear medicine is hugely capable of treating cancer and cardiac diseases. There is significant evidence, which proves that diagnosing with nuclear imaging techniques has more impact on patient management for monitoring tumors and also their response to the drug.

The shortage of the radionuclide Tc99m is likely to hamper the market growth &nbsp;

However, the field of <a href="https://www.datamintelligence.com/research-report/nuclear-imaging-equipment-market">nuclear imaging</a> is currently observing a shortage of the radionuclide Tc99m (technetium 99), which is the most commonly used isotope for imaging the body in nuclear medicine scans. This worldwide shortage of radioisotopes will impact the majority of diagnostic scans done in the nuclear medicine clinic.

<h3>COVID-19 Impact on&nbsp;Nuclear Imaging Market Growth</h3>

The COVID-19 outbreak has significantly impacted the availability of hospital resources worldwide. This has been primarily managed by dramatically reducing in-patient and outpatient services for other diseases and implementing infection prevention and control measures. Both diagnostic and therapeutic nuclear medicine procedures declined precipitously, with countries worldwide being affected by the pandemic.

Most of the nuclear imaging scans and therapies are carried out in outpatient departments as follow-up cases whereas new studies are usually dealt with in inpatient departments after going through COVID-19 screening. Nuclear medicine lacks portable SPECT and PET scanners, and there is a constant need to inject the patient with radiopharmaceuticals so the movement of the patient is not restricted. Hence nuclear medical workers must have a thorough knowledge of precautionary measures to prevent COVID-19 transmission. A majority of heart patients who go through nuclear cardiology procedures are usually above 60&thinsp;years of age and carry other extreme health risks such as diabetes, hypertension, and chronic renal and lung diseases. All of these factors make them highly vulnerable to developing COVID-19 and have led to a decrease in the number of nuclear imaging procedures. However, many healthcare experts believe that this reduction in the number of procedures is temporary.

<h3>Nuclear Imaging Market Segments</h3>

The oncology segment is expected to grow at the fastest CAGR during the forecast period (2024-2031)&nbsp;&nbsp;&nbsp; 

The prevalence of various types of cancer has shown a significant rise over the past two decades. According to the statistics of the Lymphoma Research Foundation, each year, more than 100,000 people are diagnosed with lymphoma, and nearly one million people in the United States are living with, or are in remission from, lymphoma. It third-most-common cancer in children. The FDG-PET/CT is more sensitive than contrast-enhanced CT scan in the staging of several types of lymphoma or in detecting tumor dissemination in several solid cancers, such as breast cancer, lung cancer, and colon cancer.

In the field of oncology, PET (positron emission tomography) uses FDG (18Fluorine-2-fluoro-2-Deoxy-d-glucose) as the radiopharmaceutical, as it demonstrates the increased metabolism by malignant cells when compared to that of normal cells. Furthermore, there is continuous technological progress in the field of image generation. The introduction of sophisticated software to use PET scans as a biomarker has facilitated new ways to calculate new prognostic markers, such as the metabolic tumor volume (MTV) and the total amount of tumor glycolysis (TLG). The 18F-fluorodeoxyglucose (18F-FDG) has high sensitivity, but it is not tumor-specific. This technique can be used for the imaging of lung cancer, lymphoma, head and neck tumors, breast cancer, esophageal cancer, colorectal cancer, and urinary tract tumors. Hence, all the aforementioned technological advancements are expected to drive growth in this segment of the market studied, over the forecast period.

<h3>Nuclear Imaging Market Geographical Share</h3>

North America region holds the largest market share of the global nuclear imaging market 

North America is expected to dominate the global nuclear imaging market in the forecast period. In 2016, the AMIPA (American Medical Isotope Production Act) and the DOE/NNSA (Department of Energy) established a Uranium Lease and Take-Back (ULTB) program in the United States. Under this program, the DOE/NNSA makes LEU (Low Enriched Uranium) available through lease contracts for the irradiation and production of Mo99 for medical uses. The AMIPA not only promotes the domestic production of Mo-99 but also aims to replace the role of HEU (High Enriched Uranium) in the production of medical radioactive isotopes.

Moreover, Canada is one of the largest producers of Technetium-99m. With the use of Tc-99m in radiopharmaceuticals, the market is expected to grow at a tremendous rate in Canada. It is also combined with a variety of biologically active molecules to perform non-invasive, real-time imaging of the human body.

Furthermore, there has been increasing awareness among people in this region about nuclear medicine treatment and diagnosis, which, in turn, has increased the prescriptions by physicians. These factors will drive the growth of the market in the forecast period.

<h3>Nuclear Imaging Companies and Competitive Landscape</h3>

The nuclear imaging market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Bracco Imaging SpA, Cardinal Health Inc., GE Healthcare, Koninklijke Philips NV, Siemens Healthineers, Curium, CMR NAVISCAN (GAMMA MEDICA INC.), Nordion (Canada) Inc., NTP Radioisotopes SOC, Canon Medical Systems Corporation among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Nuclear Imaging Market globally. For instance, in May 2018, Curium enhanced its position in the French PET market with the acquisition of Cyclopharma&rsquo;s French commercial and manufacturing operations.

GE Healthcare Inc. 

Overview: 

GE Healthcare Inc. produces medical equipment. The Company offers scanners, monitors, dispensers, imagers, displays, recorders, analyzers, separators, and other laboratory and medical equipment for medical and medical research industries worldwide.&nbsp; &nbsp;

Product Portfolio:

NM 830: SPECT&rsquo;s ability to reveal physiologic and metabolic changes gives you a unique tool for diagnosing and treating patients. It&rsquo;s this ability to make visible what could normally be invisible that enables true discovery in nuclear medicine. Whether you&rsquo;re looking for your first nuclear medicine camera or you need one to handle overflow from your rising patient volume, our SPECT-only system is designed to grow with your practice with a lower initial investment.

<ul>
</ul>

<ol>
	<li>
	Methodology and Scope

	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>
	Market Definition and Overview
	</li>
	<li>
	Executive Summary

	<ol>
		<li>Market Snippet By Product Type</li>
		<li>Market snippet By Application</li>
		<li>Market Snippet By End User</li>
		<li>Market Snippet by Region</li>
	</ol>
	</li>
	<li>
	Market Dynamics

	<ol>
		<li>Market Impacting Factors
		<ol>
			<li>Drivers
			<ol>
				<li>Rise in the Prevalence of Cancer and Cardiac Disorders</li>
				<li>Increase in Technological Advancements</li>
			</ol>
			</li>
			<li>Restraints:
			<ol>
				<li>The shortage of the radionuclide Tc99m</li>
			</ol>
			</li>
			<li>Opportunity</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	Industry Analysis

	<ol>
		<li>Porter&#39;s Five Forces Analysis</li>
		<li>Supply Chain Analysis</li>
		<li>Regulatory Analysis</li>
	</ol>
	</li>
	<li>
	COVID-19 Analysis

	<ol>
		<li>Analysis of Covid-19 on the Market
		<ol>
			<li>Before the COVID-19 Market Scenario</li>
			<li>Present COVID-19 Market Scenario</li>
			<li>After COVID-19 or a Future Scenario</li>
		</ol>
		</li>
		<li>Pricing Dynamics Amid Covid-19</li>
		<li>Demand-Supply Spectrum</li>
		<li>Government Initiatives Related to the Market During the Pandemic</li>
		<li>Manufacturers Strategic Initiatives</li>
		<li>Conclusion&nbsp;</li>
	</ol>
	</li>
	<li>
	By Product Type

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment</li>
			<li>Market Attractiveness Index, By Product Type Segment</li>
		</ol>
		</li>
		<li>Hybrid Pet*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028</li>
		</ol>
		</li>
		<li>Standalone Pet</li>
		<li>Hybrid SPECT</li>
		<li>Standalone SPECT</li>
		<li>Planar Scintigraphy</li>
	</ol>
	</li>
	<li>
	By Application

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Attractiveness Index, By Application</li>
		</ol>
		</li>
		<li>Cardiology*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028</li>
		</ol>
		</li>
		<li>Neurology</li>
		<li>Oncology</li>
		<li>Others</li>
	</ol>
	</li>
	<li>
	By End User

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Attractiveness Index, By End User Segment</li>
		</ol>
		</li>
		<li>Hospitals*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028</li>
		</ol>
		</li>
		<li>Research Centers</li>
		<li>&nbsp;Academic Centers</li>
		<li>Diagnostic Centers</li>
		<li>&nbsp;Others</li>
	</ol>
	</li>
	<li>
	By Region

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region</li>
			<li>Market Attractiveness Index, By Region</li>
		</ol>
		</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>The U.S.</li>
				<li>Canada</li>
				<li>Mexico</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Germany</li>
				<li>The U.K.</li>
				<li>France</li>
				<li>Italy</li>
				<li>Spain</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia Pacific
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>China</li>
				<li>India</li>
				<li>Japan</li>
				<li>Australia</li>
				<li>Rest of Asia Pacific</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Middle East and Africa
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	Competitive Landscape

	<ol>
		<li>Key Developments and Strategies</li>
		<li>Company Share Analysis</li>
		<li>Product Benchmarking</li>
	</ol>
	</li>
	<li>
	Company Profiles

	<ol>
		<li>Bracco Imaging SpA*
		<ol>
			<li>Company Overview</li>
			<li>Product Portfolio and Description</li>
			<li>Key Highlights</li>
			<li>Financial Overview</li>
		</ol>
		</li>
		<li>Cardinal Health Inc.</li>
		<li>GE Healthcare</li>
		<li>Koninklijke Philips NV</li>
		<li>Siemens Healthineers</li>
		<li>Curium</li>
		<li>CMR NAVISCAN (GAMMA MEDICA INC.)</li>
		<li>Nordion (Canada) Inc.</li>
		<li>NTP Radioisotopes SOC</li>
		<li>Canon Medical Systems Corporation(*LIST NOT EXHAUSTIVE)</li>
	</ol>
	</li>
	<li>
	DataM Intelligence

	<ol>
		<li>Appendix</li>
		<li>About Us and Services</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

List of Tables

Table 01 Global Nuclear Imaging Market Value, By Product Type, 2023, 2027 &amp; 2031 (US Million)

Table 02 Global Nuclear Imaging Market Value, By Application, 2023, 2027 &amp; 2031 (US Million)

Table 03 Global Nuclear Imaging Market Value, By End-User, 2023, 2027 &amp; 2031 (US Million)

Table 04 Global Nuclear Imaging Market Value, By Region, 2023, 2027 &amp; 2031 (US Million)

Table 05 Global Nuclear Imaging Market Value, By Product Type, 2023, 2027 &amp; 2031 (US Million)

Table 06 Global Nuclear Imaging Market Value, By Product Type, 2022-2031 (US Million)

Table 07 Global Nuclear Imaging Market Value, By Application, 2023, 2027 &amp; 2031 (US Million)

Table 08 Global Nuclear Imaging Market Value, By Application, 2022-2031 (US Million)

Table 09 Global Nuclear Imaging Market Value, By End-User, 2023, 2027 &amp; 2031 (US Million)

Table 10 Global Nuclear Imaging Market Value, By End-User, 2022-2031 (US Million)

Table 11 Global Nuclear Imaging Market Value, By Region, 2023, 2027 &amp; 2031 (US Million)

Table 12 Global Nuclear Imaging Market Value, By Region, 2022-2031 (US Million)

Table 13 North America Nuclear Imaging Market Value, By Product Type, 2022-2031 (US Million)

Table 14 North America Nuclear Imaging Market Value, By Application, 2022-2031 (US Million)

Table 15 North America Nuclear Imaging Market Value, By End-User, 2022-2031 (US Million)

Table 16 North America Nuclear Imaging Market Value, By Country, 2022-2031 (US Million)

Table 17 South America Nuclear Imaging Market Value, By Product Type, 2022-2031 (US Million)

Table 18 South America Nuclear Imaging Market Value, By Application, 2022-2031 (US Million)

Table 19 South America Nuclear Imaging Market Value, By End-User, 2022-2031 (US Million)

Table 20 South America Nuclear Imaging Market Value, By Country, 2022-2031 (US Million)

Table 21 Europe Nuclear Imaging Market Value, By Product Type, 2022-2031 (US Million)

Table 22 Europe Nuclear Imaging Market Value, By Application, 2022-2031 (US Million)

Table 23 Europe Nuclear Imaging Market Value, By End-User, 2022-2031 (US Million)

Table 24 Europe Nuclear Imaging Market Value, By Country, 2022-2031 (US Million)

Table 25 Asia-Pacific Nuclear Imaging Market Value, By Product Type, 2022-2031 (US Million)

Table 26 Asia-Pacific Nuclear Imaging Market Value, By Application, 2022-2031 (US Million)

Table 27 Asia-Pacific Nuclear Imaging Market Value, By End-User, 2022-2031 (US Million)

Table 28 Asia-Pacific Nuclear Imaging Market Value, By Country, 2022-2031 (US Million)

Table 29 Middle East &amp; Africa Nuclear Imaging Market Value, By Product Type, 2022-2031 (US Million)

Table 30 Middle East &amp; Africa Nuclear Imaging Market Value, By Application, 2022-2031 (US Million)

Table 31 Middle East &amp; Africa Nuclear Imaging Market Value, By End-User, 2022-2031 (US Million)

Table 32 Bracco Imaging SpA: Overview

Table 33 Bracco Imaging SpA: Product Portfolio

Table 34 Bracco Imaging SpA: Key Developments

Table 35 Cardinal Health Inc.: Overview

Table 36 Cardinal Health Inc.: Product Portfolio

Table 37 Cardinal Health Inc.: Key Developments

Table 38 GE Healthcare: Overview

Table 39 GE Healthcare: Product Portfolio

Table 40 GE Healthcare: Key Developments

Table 41 Koninklijke Philips NV: Overview

Table 42 Koninklijke Philips NV: Product Portfolio

Table 43 Koninklijke Philips NV: Key Developments

Table 44 Siemens Healthineers: Overview

Table 45 Siemens Healthineers: Product Portfolio

Table 46 Siemens Healthineers: Key Developments

Table 47 Curium: Overview

Table 48 Curium: Product Portfolio

Table 49 Curium: Key Developments

Table 50 CMR NAVISCAN (GAMMA MEDICA INC.): Overview

Table 51 CMR NAVISCAN (GAMMA MEDICA INC.): Product Portfolio

Table 52 CMR NAVISCAN (GAMMA MEDICA INC.): Key Developments

Table 53 Nordion (Canada) Inc.: Overview

Table 54 Nordion (Canada) Inc.: Product Portfolio

Table 55 Nordion (Canada) Inc.: Key Developments

Table 56 NTP Radioisotopes SOC: Overview

Table 57 NTP Radioisotopes SOC: Product Portfolio

Table 58 NTP Radioisotopes SOC: Key Developments

Table 59 Canon Medical Systems Corporation: Overview

Table 60 Canon Medical Systems Corporation: Product Portfolio

Table 61 Canon Medical Systems Corporation: Key Developments

&nbsp;List of Figures

Figure 01 Global Nuclear Imaging Market Share, By Product Type, 2022 &amp; 2031 (%)

Figure 02 Global Nuclear Imaging Market Share, By Application, 2022 &amp; 2031 (%)

Figure 03 Global Nuclear Imaging Market Share, By End-User, 2022 &amp; 2031 (%)

Figure 04 Global Nuclear Imaging Market Share, By Region, 2022 &amp; 2031 (%)

Figure 05 Global Nuclear Imaging Market Value, 2022-2031 (US Million)

Figure 06 Global Nuclear Imaging Market Y-o-Y Growth, By Product Type, 2022-2031 (%)

Figure 07 Hybrid Pet: Global Nuclear Imaging Market Value, 2022-2031 (US Million)

Figure 08 Standalone Pet: Global Nuclear Imaging Market Value, 2022-2031 (US Million)

Figure 09 Hybrid SPECT: Global Nuclear Imaging Market Value, 2022-2031 (US Million)

Figure 10 Standalone SPECT: Global Nuclear Imaging Market Value, 2022-2031 (US Million)

Figure 11 Planar Scintigraphy: Global Nuclear Imaging Market Value, 2022-2031 (US Million)

Figure 12 Global Nuclear Imaging Market Y-o-Y Growth, By Application, 2022-2031 (%)

Figure 13 Cardiology: Global Nuclear Imaging Market Value, 2022-2031 (US Million)

Figure 14 Neurology: Global Nuclear Imaging Market Value, 2022-2031 (US Million)

Figure 15 Oncology: Global Nuclear Imaging Market Value, 2022-2031 (US Million)

Figure 16 Others: Global Nuclear Imaging Market Value, 2022-2031 (US Million)

Figure 17 Global Nuclear Imaging Market Y-o-Y Growth, By End-User, 2022-2031 (%)

Figure 18 Hospitals: Global Nuclear Imaging Market Value, 2022-2031 (US Million)

Figure 19 Research Centers: Global Nuclear Imaging Market Value, 2022-2031 (US Million)

Figure 20 Academic Centers: Global Nuclear Imaging Market Value, 2022-2031 (US Million)

Figure 21 Diagnostic Centres: Global Nuclear Imaging Market Value, 2022-2031 (US Million)

Figure 22 Others: Global Nuclear Imaging Market Value, 2022-2031 (US Million)

Figure 23 Global Nuclear Imaging Market Y-o-Y Growth, By Region, 2022-2031 (%)

Figure 24 North America Nuclear Imaging Market Value, 2022-2031 (US Million)

Figure 25 North America Nuclear Imaging Market Share, By Product Type, 2022 &amp; 2031 (%)

Figure 26 North America Nuclear Imaging Market Share, By Application, 2022 &amp; 2031 (%)

Figure 27 North America Nuclear Imaging Market Share, By End-User, 2022 &amp; 2031 (%)

Figure 28 North America Nuclear Imaging Market Share, By Country, 2022 &amp; 2031 (%)

Figure 29 South America Nuclear Imaging Market Value, 2022-2031 (US Million)

Figure 30 South America Nuclear Imaging Market Share, By Product Type, 2022 &amp; 2031 (%)

Figure 31 South America Nuclear Imaging Market Share, By Application, 2022 &amp; 2031 (%)

Figure 32 South America Nuclear Imaging Market Share, By End-User, 2022 &amp; 2031 (%)

Figure 33 South America Nuclear Imaging Market Share, By Country, 2022 &amp; 2031 (%)

Figure 34 Europe Nuclear Imaging Market Value, 2022-2031 (US Million)

Figure 35 Europe Nuclear Imaging Market Share, By Product Type, 2022 &amp; 2031 (%)

Figure 36 Europe Nuclear Imaging Market Share, By Application, 2022 &amp; 2031 (%)

Figure 37 Europe Nuclear Imaging Market Share, By End-User, 2022 &amp; 2031 (%)

Figure 38 Europe Nuclear Imaging Market Share, By Country, 2022 &amp; 2031 (%)

Figure 39 Asia-Pacific Nuclear Imaging Market Value, 2022-2031 (US Million)

Figure 40 Asia-Pacific Nuclear Imaging Market Share, By Product Type, 2022 &amp; 2031 (%)

Figure 41 Asia-Pacific Nuclear Imaging Market Share, By Application, 2022 &amp; 2031 (%)

Figure 42 Asia-Pacific Nuclear Imaging Market Share, By End-User, 2022 &amp; 2031 (%)

Figure 43 Asia-Pacific Nuclear Imaging Market Share, By Country, 2022 &amp; 2031 (%)

Figure 44 Middle East &amp; Africa Nuclear Imaging Market Value, 2022-2031 (US Million)

Figure 45 Middle East &amp; Africa Nuclear Imaging Market Share, By Product Type, 2022 &amp; 2031 (%)

Figure 46 Middle East &amp; Africa Nuclear Imaging Market Share, By Application, 2022 &amp; 2031 (%)

Figure 47 Middle East &amp; Africa Nuclear Imaging Market Share, By End-User, 2022 &amp; 2031 (%)

Figure 48 Bracco Imaging SpA: Financials

Figure 49 Cardinal Health Inc.: Financials

Figure 50 GE Healthcare: Financials

Figure 51 Koninklijke Philips NV: Financials

Figure 52 Siemens Healthineers: Financials

Figure 53 Curium: Financials

Figure 54 CMR NAVISCAN (GAMMA MEDICA INC.): Financials

Figure 55 Nordion (Canada) Inc.: Financials

Figure 56 NTP Radioisotopes SOC: Financials

Figure 57 Canon Medical Systems Corporation: Financials